Description

Atorvastatin 

• Drug class: HMG-CoA reductase inhibitors (statins)

• Atorvastatin is an appropriate first-line lipid-lowering therapy in numerous groups of patients at low to high risk of CHD.

• Atorvastatin competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase by doing so, helps decrease cholesterol production in the liver. 

• Atorvastatin also increases the number of LDL receptors on the surface of hepatic cells.

Clopidogrel 

• Clopidogrel is a prodrug, which needs to be metabolized in the liver into active metabolites.

• Clopidogrel efficiently reduces ADP-induced platelet aggregation (a key phenomenon in atherosclerosis & CVD) and prolongs bleeding time and is a safe and efficacious antiplatelet drug.

Aspirin 

• Drug Class: NSAIDs

• The most widely tested antiplatelet regimen was aspirin. The benefit of low-dose aspirin therapy for the secondary prevention of serious cardiovascular events is clear.

• Aspirin has long been the therapeutic foundation of the secondary prevention of CVD, to which contemporary drugs such as statins, and other antithrombotics have been added.

Combination:

• Aspirin and clopidogrel are antiplatelet agents that display good antithrombotic activity.Clopidogrel in combination with aspirin is the current “gold standard” for reducing cardiovascular events.

• Clopidogrel plus aspirin can reduce the relative risk of adverse cardiovascular events by 20%, compared with aspirin alone.

• Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation. But, statin (Atorvastatin) quickly decreases thrombosis risk and inflammation, and these effects may balance the loss of clopidogrel efficacy.